Clinical Trial

TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial is a prospective, dose-escalation, multicenter, single- arm, Phase 1 clinical trial to evaluate the safety, tolerability, PK and preliminary clinical activity of PRAME Antigen-targeted TCR-T Cells (NW-101C) infusion in patients with previously heavily treated, metastatic solid malignant tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-24.
Trial Details
NCT Number NCT07266298
Lead Sponsor Neowise Biotechnology
Conditions Solid Metastatic Tumor
Enrollment 24 participants
Start Date 2025-12
Primary Completion 2028-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-12